Tyrosine Kinase Inhibitors

The following drugs under development are similar to approved GIST treatments imatinib (Gleevec) and sunitinib (Sutent) in that they inhibit the KIT and/or PDGFR growth factor receptors.  Some of them also inhibit vascular endothelial growth factor (VEGF) or its receptors for anti-angiogenic effects.

MLN518 

Vatalanib PTK787 

OSI-930

AZD2171

Amuvatinib (MP470)

TKI258

Masitinib (AB1010)

Crenolanib  (CP-868,596)

DCC-2618